Adverum Income Quality vs Ev To Sales Analysis
ADVM Stock | USD 10.43 0.43 4.30% |
Adverum Biotechnologies financial indicator trend analysis is way more than just evaluating Adverum Biotechnologies prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adverum Biotechnologies is a good investment. Please check the relationship between Adverum Biotechnologies Income Quality and its Ev To Sales accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.
Income Quality vs Ev To Sales
Income Quality vs Ev To Sales Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adverum Biotechnologies Income Quality account and Ev To Sales. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Adverum Biotechnologies' Income Quality and Ev To Sales is 0.13. Overlapping area represents the amount of variation of Income Quality that can explain the historical movement of Ev To Sales in the same time period over historical financial statements of Adverum Biotechnologies, assuming nothing else is changed. The correlation between historical values of Adverum Biotechnologies' Income Quality and Ev To Sales is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Quality of Adverum Biotechnologies are associated (or correlated) with its Ev To Sales. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Sales has no effect on the direction of Income Quality i.e., Adverum Biotechnologies' Income Quality and Ev To Sales go up and down completely randomly.
Correlation Coefficient | 0.13 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Income Quality
An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most indicators from Adverum Biotechnologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adverum Biotechnologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.As of the 4th of May 2024, Sales General And Administrative To Revenue is likely to grow to 17.94, while Selling General Administrative is likely to drop about 31.8 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 153.6M | 157.1M | 121.7M | 81.4M | Cost Of Revenue | 4.6M | 6.5M | 5.6M | 5.4M |
Adverum Biotechnologies fundamental ratios Correlations
Click cells to compare fundamentals
Adverum Biotechnologies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Adverum Biotechnologies fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 222.7M | 482.6M | 439.7M | 308.4M | 173.0M | 247.9M | |
Other Current Liab | 2.6M | 1.3M | 2.0M | 16.8M | 12.5M | 13.1M | |
Total Current Liabilities | 19.4M | 20.9M | 21.3M | 32.2M | 24.9M | 15.0M | |
Total Stockholder Equity | 175.0M | 434.3M | 316.2M | 181.5M | 83.5M | 79.3M | |
Other Liab | 1.4M | 48K | 1.1M | 1.0M | 942.3K | 895.2K | |
Property Plant And Equipment Net | 45.8M | 47.1M | 119.1M | 113.9M | 67.0M | 37.4M | |
Net Debt | (33.6M) | (31.7M) | 68.8M | 38.4M | 36K | 37.8K | |
Retained Earnings | (385.0M) | (502.5M) | (648.1M) | (802.6M) | (919.8M) | (873.8M) | |
Accounts Payable | 4.1M | 2.8M | 1.4M | 2.2M | 1.9M | 1.9M | |
Cash | 65.9M | 62.4M | 34.2M | 68.4M | 75M | 78.2M | |
Non Current Assets Total | 46.9M | 48.1M | 122.6M | 117.8M | 70.2M | 39.7M | |
Cash And Short Term Investments | 166.0M | 429.7M | 305.2M | 185.6M | 96.5M | 91.7M | |
Common Stock Shares Outstanding | 6.4M | 8.5M | 9.8M | 9.9M | 10.1M | 18.4M | |
Liabilities And Stockholders Equity | 222.7M | 482.6M | 439.7M | 308.4M | 173.0M | 247.9M | |
Non Current Liabilities Total | 28.4M | 27.3M | 102.2M | 94.6M | 64.6M | 67.9M | |
Other Current Assets | 9.8M | 4.7M | 6.2M | 5.0M | 6.2M | 4.0M | |
Other Stockholder Equity | 560.7M | 937.1M | 965.0M | 985.7M | 1.0B | 567.3M | |
Total Liab | 47.8M | 48.2M | 123.5M | 126.9M | 89.5M | 46.9M | |
Property Plant And Equipment Gross | 24.9M | 47.1M | 132.2M | 130.9M | 81.5M | 85.6M | |
Total Current Assets | 175.9M | 434.4M | 317.1M | 190.6M | 102.8M | 97.6M | |
Accumulated Other Comprehensive Income | (725K) | (261K) | (714K) | (1.5M) | (473K) | (496.7K) | |
Property Plant Equipment | 24.9M | 27.7M | 33.1M | 113.9M | 130.9M | 137.5M | |
Non Currrent Assets Other | 11K | 29K | 250K | 1.4M | 1.2M | 1.3M | |
Other Assets | 1.0M | 1.0M | 3.5M | 3.9M | 4.5M | 4.7M | |
Net Tangible Assets | 175.0M | 434.3M | 316.2M | 181.5M | 208.7M | 256.7M | |
Common Stock Total Equity | 5K | 6K | 7K | 10K | 11.5K | 6.5K | |
Retained Earnings Total Equity | (320.5M) | (385.0M) | (502.5M) | (648.1M) | (583.3M) | (554.1M) | |
Short Term Investments | 100.1M | 367.3M | 271.0M | 117.2M | 21.5M | 20.4M | |
Capital Surpluse | 522.5M | 560.7M | 937.1M | 965.0M | 1.1B | 599.6M | |
Short Term Debt | 4.0M | 4.5M | 1.9M | 13.2M | 10.4M | 6.1M | |
Common Stock | 5K | 6K | 7K | 10K | 11.5K | 7.4K | |
Non Current Liabilities Other | 28.4M | 27.3M | 102.2M | 1.0M | 1.2M | 1.1M | |
Net Invested Capital | 175.0M | 434.3M | 316.2M | 181.5M | 83.5M | 79.3M | |
Net Working Capital | 156.5M | 413.6M | 295.8M | 158.3M | 77.9M | 74.0M |
Pair Trading with Adverum Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adverum Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adverum Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Adverum Stock
0.72 | VRAX | Virax Biolabs Group Fiscal Year End 12th of June 2024 | PairCorr |
Moving against Adverum Stock
0.6 | INDP | Indaptus Therapeutics Financial Report 9th of May 2024 | PairCorr |
0.58 | LIXT | Lixte Biotechnology Earnings Call This Week | PairCorr |
0.5 | GBIO | Generation BioCo Financial Report 8th of May 2024 | PairCorr |
0.49 | ELVN | Enliven Therapeutics Trending | PairCorr |
The ability to find closely correlated positions to Adverum Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adverum Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adverum Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adverum Biotechnologies to buy it.
The correlation of Adverum Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adverum Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adverum Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adverum Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Adverum Stock analysis
When running Adverum Biotechnologies' price analysis, check to measure Adverum Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adverum Biotechnologies is operating at the current time. Most of Adverum Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adverum Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adverum Biotechnologies' price. Additionally, you may evaluate how the addition of Adverum Biotechnologies to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Adverum Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.60) | Revenue Per Share 0.357 | Quarterly Revenue Growth (0.70) | Return On Assets (0.32) | Return On Equity (0.88) |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.